We Ran A Stock Scan For Earnings Growth And Shenzhen New Industries Biomedical Engineering (SZSE:300832) Passed With Ease
We Ran A Stock Scan For Earnings Growth And Shenzhen New Industries Biomedical Engineering (SZSE:300832) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.
对于初学者来说,购买那些向投资者讲述好故事的公司看起来可能是一个好主意(也是一个令人兴奋的前景),即使它当前缺乏营收和利润的记录。不幸的是,这些高风险的投资通常几乎没有任何回报的可能性,许多投资者为此而付出代价。亏损企业始终在争分夺秒地追求实现财务可持续性,因此这些公司的投资者可能承担了比他们应承担的风险要大。
If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Shenzhen New Industries Biomedical Engineering (SZSE:300832). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Shenzhen New Industries Biomedical Engineering with the means to add long-term value to shareholders.
如果这种公司不符合您的风格,您喜欢创业板公司,甚至是盈利的公司,那么您可能会对深圳新产业生物医药股份有限公司(SZSE:300832)感兴趣。即使这家公司的市场价值相当,投资者也会认为,持续盈利将继续为深圳新产业生物医药股份有限公司提供为股东增加长期价值的手段。
How Quickly Is Shenzhen New Industries Biomedical Engineering Increasing Earnings Per Share?
深圳新产业生物医药股份有限公司的每股收益在多快地增长?
Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Shareholders will be happy to know that Shenzhen New Industries Biomedical Engineering's EPS has grown 19% each year, compound, over three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be beaming.
一般来说,每股收益(EPS)增长的公司应该看到相似的股价趋势。因此,有很多投资者喜欢买入成长性强的EPS公司的股份。股东将很高兴地得知,深圳新产业生物医药股份有限公司的EPS每年复合增长19%,持续了三年。作为一般规则,我们会说,如果一家公司能保持这样的增长,股东们一定会感到欣喜。
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. Shenzhen New Industries Biomedical Engineering maintained stable EBIT margins over the last year, all while growing revenue 28% to CN¥4.1b. That's progress.
一种确认公司成长的方法是看它的营业收入和利润(EBIT)的利润率如何改变。深圳新产业生物医药股份有限公司在过去一年中保持了稳定的EBIT利润率,同时营收增长了28%,达到了41亿人民币。这是有进步的。
In the chart below, you can see how the company has grown earnings and revenue, over time. To see the actual numbers, click on the chart.
在下面的图表中,您可以看到公司的盈利和营业收入随时间的增长情况。要查看实际数字,请单击图表。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240724/0-09ca69c40266147cb4111744db38d7d4-0-6377eac33901542eea73bd1032d4a574.png/big)
You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Shenzhen New Industries Biomedical Engineering's future profits.
你不会一边开车一边看后视镜,所以你可能更感兴趣的是这份免费报告,显示了分析师对深圳新产业生物医药股份有限公司未来利润的预测。
Are Shenzhen New Industries Biomedical Engineering Insiders Aligned With All Shareholders?
深圳新产业生物医药股份有限公司的内部人士是否与所有股东保持一致?
Since Shenzhen New Industries Biomedical Engineering has a market capitalisation of CN¥50b, we wouldn't expect insiders to hold a large percentage of shares. But we do take comfort from the fact that they are investors in the company. We note that their impressive stake in the company is worth CN¥9.4b. This totals to 19% of shares in the company. Enough to lead management's decision making process down a path that brings the most benefit to shareholders. Very encouraging.
由于深圳新产业生物医药股份有限公司的市值为500亿元人民币,我们不会期望内部人士持有大量股份。但我们从他们是公司的投资者这个事实中得到了一些安慰。我们注意到,他们在公司的持股中所占比例值94亿元,占公司股份总数的19%。这足以引导管理层做出对股东最有益的决策。非常鼓舞人心。
Should You Add Shenzhen New Industries Biomedical Engineering To Your Watchlist?
你应该将深圳新产业生物医药股份有限公司加入你的自选吗?
For growth investors, Shenzhen New Industries Biomedical Engineering's raw rate of earnings growth is a beacon in the night. This EPS growth rate is something the company should be proud of, and so it's no surprise that insiders are holding on to a considerable chunk of shares. On the balance of its merits, solid EPS growth and company insiders who are aligned with the shareholders would indicate a business that is worthy of further research. It is worth noting though that we have found 1 warning sign for Shenzhen New Industries Biomedical Engineering that you need to take into consideration.
对于成长性投资者来说,深圳新产业生物医药股份有限公司的每股收益增长速度就如同黑夜中的灯塔。这种EPS增长率是公司应该引以为傲的,因此,公司内部人士持有相当大的一部分股份也就不足为奇了。在衡量其优点的平衡中,坚实的EPS增长和内部人士与股东的一致意见表明,该企业值得进一步研究。值得注意的是,我们还发现了1个对深圳新产业生物医药股份有限公司构成警告的迹象。
There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a tailored list of Chinese companies which have demonstrated growth backed by significant insider holdings.
总是有可能购买没有盈利增长并且内部人不买股票的股票而获得成功。但对于那些认为这些指标很重要的人,我们鼓励您查看具有这些特征的公司。您可以访问一份定制的中资企业列表,这些企业展示了由重要内部股份持有支持的增长。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
请注意,本文讨论的内部交易是指在相关司法管辖区中报告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。